Dr. Alan Fleischer MD
Professor and Chair of Dermatology, Wake Forest University School of Medicine - CC
Member of the Healthcare Council
Council Member Biography
Alan Fleischer, MD, is a Professor and Chair of Dermatology at the Wake Forest University School of Medicine. In addition to his general and surgical dermatology practice, he has been the primary investigator on dozens of Phase II through Phase IV clinical trials. Dr. Fleischer has published extensively on the delivery of dermatologic healthcare in the U.S. The primary disease states he has investigated include the inflammatory diseases, especially psoriasis, atopic dermatitis, urticaria, acne and rosacea. Dr. Fleischer consults for several pharmaceutical companies and has ongoing grant support for his research efforts. (This is me - Update Profile)
Employment History
- 1991 - Unspecified
- Professor and Chair of Dermatology, Wake Forest University School of Medicine - CC
GLG NewsSM Analyses by Alan Fleischer(?)
Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
-
Probiotics and Atopic Dermatitis
April 27, 2009
Probiotics for the treatment or prevention of atopic dermatitis: a review of the evidence from randomized controlled trials. | www.ncbi.nlm.nih.gov
Large, well-conducted meta-analysis shows as a preventative strategy, probiotics may have a modest effect on decreasing the incidence of atopic eczema. However, in terms of treating active disease or preventing recurrence of disease, no convincing evidence supports the use of the probiotics examined thus far.
Leading institutions connect with Alan Fleischer through GLG
GLG Study Groups with Alan Fleischer(?)
| Study Group Name | No. Members |
|---|---|
| Real Estate Experts (Asia) | 1768 |
| Dermatologists (US) | 616 |
| Physicians who Treat Acne (US) | 302 |
| Physicians who Treat Rosacea (US) | 134 |
| Physicians who Treat Onychomycosis (US) | 121 |
GLG Live Meetings with Alan Fleischer(?)
Alan Fleischer has not participated in any GLG Live Meetings.